ArticlePloS one2017
Cerebellar volume as imaging outcome in progressive multiple sclerosis.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.European radiology · 2022Trial
- Brain Atrophy and Cognitive Impairment in Primary and Secondary Progressive Multiple Sclerosis Cohort-Similar Progressive MS Phenotype.International journal of molecular sciences · 2025Article
- Volumetric and diffusion MRI abnormalities associated with dysarthria in multiple sclerosis.Brain communications · 2024Article
- Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review.Clinical neuroradiology · 2022Review
- Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course.Frontiers in neurology · 2022Article
- Cerebellar volume loss in radiologically isolated syndrome.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Laminar analysis of the cortical T1/T2-weighted ratio at 7T.Neurology(R) neuroimmunology & neuroinflammation · 2020Observational
- 2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis.European radiology · 2020Article
- Monitoring Progressive Multiple Sclerosis with Novel Imaging Techniques.Neurology and therapy · 2018Review
- Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?Journal of neurology · 2018Article
- An MRI evaluation of grey matter damage in African Americans with MS.Multiple sclerosis and related disorders · 2018Article
- Longitudinal Preterm Cerebellar Volume: Perinatal and Neurodevelopmental Outcome Associations.Cerebellum (London, England) · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeTo assess whether cerebellar volumes changes could represent a sensitive outcome measure in primary-progressive MS. MATERIAL AND
methodsChanges in cerebellar volumes over one-year follow-up, estimated in 26 primary-progressive MS patients and 20 controls with Freesurfer longitudinal pipeline, were assessed using Wilcoxon test and tested for their correlation with disability worsening by a logistic regression. Clinical worsening was defined as EDSS score increase or change of >20% for 25-foot walk test or 9-hole peg test scores at follow-up. Sample sizes for given treatment effects and power were calculated. The findings were validated in an independent cohort of 20 primary-progressive MS patients.
resultsSignificant changes were detected in brain T1 lesion volume (p<0.01), cerebellar T2 and T1 lesion volume (p<0.01 and p<0.05), cerebellar volume, cerebellar cortex volume, and cerebellar WM volume (p<0.001). Only cerebellar volume and cerebellar cortex volume percentage change were significantly reduced in clinically progressed patients when compared to patients who did not progress (p<0.01; respectively AUC of 0.91 and 0.96). Cerebellar volume percentage changes were consistent in the exploration and validation cohorts (cerebellar volume -1.90±1.11% vs -1.47±2.30%; cerebellar cortex volume -1.68±1.41% vs -1.56±2.23%). Based on our results the numbers of patients required to detect a 30% effect are 81 per arm for cerebellar volume and 162 per arm for cerebellar cortex volume (90% power, type 1 error alpha = 0.05).
conclusionsOur results suggest a role for cerebellar cortex volume and cerebellar volume as potential short-term imaging metrics to monitor treatment effect in primary-progressive MS clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.